参麦注射液在支气管动脉介入治疗中晚期肺癌的应用及临床疗效分析
Analysis of the clinical efficacy of Shenmai Injection and bronchus artery intervention therapy on metaphase or terminal lung cancer
张学钰 1陈中书 1凌东进 1冯剑雄 1施天生1
作者信息
摘要
目的探讨参麦注射液辅助支气管动脉介入治疗中晚期肺癌的临床疗效及安全性。方法将82例中晚期肺癌患者分为观察组(53例)和对照组(29例)，对照组予支气管动脉介入治疗，观察组在此基础上加用参麦注射液辅助治疗，观察两组患者治疗疗效及毒副反应情况。结果观察组治疗有效率71.69%，明显高于对照组的55.17%(P <0.05)；观察组出现恶心呕吐及白细胞减少病例明显低于对照组(P <0.05)，1年生存率、2年生存率均明显高于对照组(P <0.05)。结论在支气管动脉介入治疗基础上加用参麦注射液辅助治疗中晚期肺癌，可有效提高疗效，减少毒副反应。
Abstract
Objective To investigate the clinical efficacy and safety of Shenmai Injection and bronchus artery intervention therapy on the treatment of metaphase or terminal lung cancer. Methods 82 cases of metaphase or terminal lung cancer were divided into the observation group(with 53 cases) and the control group(with 29 cases). The control group was treated with bronchus artery intervention therapy, while the observation group was additionally treated Shenmai Injection. Observations were carried out about the clinical efficacy and toxic and side effects of both groups. Results The effective treatment rate of the observation group was 71.69%, significantly higher than 55.17% of the control group(P <0.05). The cases in the observation group with nausea and vomiting as well as leucopenia were fewer than those in the control group(P <0.05). The one-year rate of survivors and two-year rate of survivors of the observation group were significantly higher than those of the control group(P <0.05). Conclusion With the qualities of effectively improving clinical efficacy and reducing toxic and side effects, Shenmai.
关键词
中晚期肺癌/支气管动脉介入治疗/参麦注射液Key words
Metaphase or terminal lung cancer/Bronchus artery interventional therapy/Shenmai Injection引用本文复制引用
出版年
2013
NETL
NSTL
维普
万方数据